Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo

Circulation

Volumn 96, Issue 5, 1997, Pages 1612-1615

  Biemond, Bart J ^c   Friederich, Philip W ^c   Koschinsky, Marlys L ^a   Levi, Marcel ^b   Sangrar, Waheed ^a   Xia, Jiazhi ^a   Büller, Harry R ^c   Ten Cate, Jan W ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NONE

Author keywords

Apolipoprotiens; Fibrinolysis; Plasminogen; Plasminogen activators; Thrombolysis

Indexed keywords

APOLIPOPROTEIN A; ENZYME PRECURSOR; PLASMINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY RISK; FIBRINOLYSIS; JUGULAR VEIN; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; RABBIT; VEIN THROMBOSIS;

EID: 0030858202     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.5.1612     Document Type: Article

References (31)

1. Rhoads GG, Dahlen GH, Berg K, Morton ME, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1987;256:2540-2544.
2. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
3. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10: 240-245.
4. Koschinsky ML, Cote GP, Gabel B, van der Hoek YY. Identification of the cysteine residue in apolipoprotein(a) which mediates extracellular coupling with apolipoprotein B-100. J Biol Chem. 1993;268:19819-19825.
5. Fless GM, ZumMallen ME, Scanu AM. Physiochemical properties of apoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem. 1986;261:8712-8718.
6. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 1987;300: 132-137.
7. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
8. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. J Clin Invest. 1987;80: 458-465.
9. Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989;86:3847-3851.
10. Rouy D, Koschinsky ML, Fleury V, Chapman J, Angles-Cano E. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry. 1992;31:6333-6339.
11. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
12. Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry. 1993;32:4628-4633.
13. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;1:256-259.
14. Koschinsky ML, Tomlinson JE, Zioncheck TF, Schwartz K, Eaton DL, Lawn RM. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 1991;30:5044-5051.
15. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro. Biochemistry. 1995;34:5151-5157.
16. van der Hoek YY, Kastelein JJP, Koschinsky ML. Analysis of structure-function relationships in human apolipoprotein(a). Can J Physiol Pharmacol. 1994;72:304-310.
17. Graham FL, van der Erb AJ. A new technique for the assay of infectivity of human adenovirus IV DNA. Virology. 1973;52: 456-467.
18. Wong WLT, Eaton DL, Berloni A, Fendly B, Hass PE. A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). Clin Chem. 1990;36:192-197.
19. Wiseman S, Kencington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM, Powell JT. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ. 1989;299: 643-646.
20. Krempler F, Kostner GM, Rascher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest. 1983;71: 1431-1441.
21. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987;330:113-114.
22. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-1319.
23. von Hodenberg E, Kreuzer J. Effect of lipoprotein(a) on success rate of thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 1991;67:1349-1353.
24. Hoyaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem. 1982;257:2912-2919. Tissue type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein.
25. Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry. 1991;30: 6671-6677.
26. Edelberg JM, Gonzalez-Gronow, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res. 1990;57:155-162.
27. Lu H, Bruckert J, Soria J, Li H, de Gennes JL, Legrand A, Peynet J, Soria C. Absence of lipoprotein(a) inhibition of t-PA induced thrombolysis in a patients plasma milieu. Blood Coagul Fibrinolysis. 1990;1:513-516.
28. Sundell IB, Nilson TK, Hallmans G, Hellsten G, Dahlen GH. Interrelationships between plasma levels of plasminogen activator inhibitor, lipoprotein(a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis. 1989;80:9-16.
29. Halvorsen S, Skønsberg OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res. 1992; 68:223-232.
30. Kojima S, Harpel PC, Rifkin DB. Lipoprotein(a) inhibits the generation of transforming growth factor: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991;13:1439-1445.
31. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.